Submit Release

EIN Presswire is celebrating 30 years! Follow us on Substack for customer insights, interviews, and more!

World Media Directory · RSS · Email Newsletters

There were 1,774 press releases posted in the last 24 hours and 321,837 in the last 365 days.

b3c newswire Press Releases

1,798 Press Releases

Published on September 12, 2017 - 09:58 GMT

Successful Industrial GMP Manufacturing of RIBOXXIM, a Novel and Highly Potent Toll-like 3 Ligand for Immunotherapy of Cancer

Radebeul, Germany & Lyon, France, September 12, 2017 / B3C newswire / -- RIBOXX PHARMACEUTICALS, a biotech company developing Toll-like-receptor (TLR) and RIG-I-like-Receptor (RLR) ligands, and ACCINOV, a pharmaceutical establishment for experimental …

Distribution channels: Technology
Published on September 11, 2017 - 07:08 GMT

New Analysis from German Study Group Prospective Trial Shows Minimal Distant Recurrence in Patients with Clinically High-Risk ...

Additional large population-based study indicates not all young women under 40 years with node negative breast cancer have aggressive disease-excellent survival without chemotherapy reported at five years for patients with low Recurrence Score® results …

Distribution channels: Technology
Published on September 8, 2017 - 10:47 GMT

Robust Performance of OncoBEAM™ RAS CRC Liquid Biopsy Testing in Routine Clinical Practice for Colorectal Cancer Patients ...

Hamburg, Germany, September 08, 2017 / B3C newswire / -- Sysmex Inostics, a subsidiary of Sysmex Corporation, a global leader in blood based circulating tumor DNA (ctDNA) analysis and molecular diagnostics for oncology is pleased to announce new data from …

Distribution channels: Technology
Published on September 6, 2017 - 08:35 GMT

Congenica’s Sapientia™ Selected by Coimbra Paediatric Hospital for Portugal’s In2Genome Genetic Disease Diagnosis Project

Cambridge, UK, September 06, 2017 / B3C newswire / -- Congenica, a global provider of clinical genomics interpretation software, today announced a new customer partnership with the Coimbra Paediatric Hospital (CPH), a leading paediatric hospital in …

Distribution channels: Technology
Published on September 5, 2017 - 08:43 GMT

AMAL Therapeutics Raises EUR 8 Million (CHF 8.8 Million) in First Closing of Series B Financing Round

Financing round co-led by Boehringer Ingelheim Venture Fund, BioMedPartners and Helsinn Investment Fund Funds will be used to support: Clinical development of lead vaccine (ATP128) for colorectal cancer through to clinical proof-of-concept Further …

Distribution channels: Technology
Published on September 1, 2017 - 13:30 GMT

Asian Study of Over 15,000 Mammograms Underlines the Potential Value of Sigmascreening’s Sensitive Sigma™ Paddle Solution for ...

Amsterdam, The Netherlands, September 01, 2017 / B3C newswire / -- Sigmascreening, a Dutch MedTech developer and world leader in the field of pressure based digital mammography and breast cancer screening, announces that a study of in total 15,898 in …

Distribution channels: Technology
Published on August 22, 2017 - 08:36 GMT

Orchard Therapeutics Announces That OTL-101 Has Received a Designation as Promising Innovative Medicine by UK’s Regulatory Agency

London, UK, August 22, 2017 / B3C newswire / -- Orchard Therapeutics Limited (“Orchard”), a clinical-stage biotechnology company developing transformative gene therapies for patients with severe inherited orphan diseases, today announces that the UK …

Distribution channels: Technology
Published on August 21, 2017 - 07:36 GMT

Immatics Initiates Personalized Adoptive Cellular Therapy in Patients with Relapsed And/Or Refractory Solid Cancers Using Its ...

Houston, Texas, USA and Tuebingen, Germany, August 21, 2017 / B3C newswire / -- Immatics, a leading company in the field of cancer immunotherapy, today announced that it has initiated enrolment of patients into a phase I trial of its first adoptive …

Distribution channels: Technology
Published on August 17, 2017 - 12:43 GMT

RedHill Biopharma Announces U.S. Commercialization Agreement for FDA-Approved GI Product Esomeprazole Strontium Delayed-Release ...

RedHill was granted the exclusive rights to promote Esomeprazole Strontium Delayed-Release (DR) Capsules to gastroenterologists in certain U.S. territories Esomeprazole Strontium DR Capsules 49.3 mg is an FDA-approved, proprietary, prescription proton pump …

Distribution channels: Technology
Published on August 16, 2017 - 07:35 GMT

MIMETAS Develops High-Throughput Gut-on-a-chip Technology in Collaboration with Pharmaceutical Company

Leiden, the Netherlands, August 16, 2017 / B3C newswire / -- MIMETAS, in collaboration with the pharmaceutical company Roche (Basel), has developed a novel organ-on-a-chip system that supports evaluation of intestinal permeability in perfused 3D gut …

Distribution channels: Technology
Published on August 10, 2017 - 14:44 GMT

RedHill Biopharma Provides 2017 Semi-Annual Business Update

RedHill’s U.S. gastrointestinal (GI)-focused sales force is promoting two specialty products, setting the stage for the potential launch of RedHill’s late clinical-stage GI products, if approved, and for the acquisition of additional commercial GI products …

Distribution channels: Technology
Published on August 10, 2017 - 08:30 GMT

Orchard Therapeutics Appoints Mark Rothera as CEO

London, UK, August 10, 2017 / B3C newswire / -- Orchard Therapeutics (“Orchard”), a clinical-stage biotechnology company developing transformative gene therapies for patients with severe and life-threatening inherited diseases, today announces the …

Distribution channels: Technology
Published on July 31, 2017 - 13:46 GMT

RedHill Biopharma Announces Unanimous Positive DSMB Recommendation for Continuation of the Phase III Study with RHB-104 for Crohn'...

The independent Data and Safety Monitoring Board (DSMB) reviewed safety and efficacy data, of which RedHill remains blinded, from the first 222 subjects who have completed week 26 assessments in the Phase III MAP US study To date, over 300 of the planned …

Distribution channels: Technology
Published on July 31, 2017 - 08:41 GMT

BioScience Managers Appoints Elizabeth Klein as Investment Consultant in the UK to Support BioScience Managers' and Downing's Life ...

London, UK and Melbourne, Australia, July 31, 2017 / B3C newswire / -- Leading healthcare investment specialist BioScience Managers Limited (BioScience Managers) announces today that it has appointed Elizabeth Klein as an Investment Consultant, to …

Distribution channels: Technology
Published on July 25, 2017 - 12:18 GMT

BioGenes Celebrates 25 Years of Excellence in Quality Control of Biotherapeutics

Berlin, Germany, July 25, 2017 / B3C newswire / -- BioGenes GmbH, specializing in ELISA development and production, is celebrating its 25-year anniversary. In 1992 the scientists Dr. Alexander Knoll and Dr. Sergej Ovodov set out with a vision to provide …

Distribution channels: Technology
Published on July 25, 2017 - 09:43 GMT

Unicyte AG, Regenerative Medicine Unit of Fresenius Medical Care, Appoints World-Leading Experts to Scientific Advisory Board

Oberdorf, Switzerland, July 25, 2017 / B3C newswire / -- Unicyte AG, a pioneering leader in human liver stem cells and nano-extracellular vesicles, announced today the formation of its inaugural Scientific Advisory Board with the appointments of Professors …

Distribution channels: Technology
Published on July 25, 2017 - 07:20 GMT

ANTABIO Awarded Up to USD8.9M from CARB-X to Accelerate the Development of Its New Treatment For Chronic Infections in Cystic ...

Labège, France, July 25, 2017 / B3C newswire / -- Antabio SAS, a biopharmaceutical company developing novel antibacterial treatments in areas of highest unmet needs, announced today that it has been awarded up to $8.9 million non-dilutive funding from CARB …

Distribution channels: Technology
Published on July 24, 2017 - 08:34 GMT

Orchard Therapeutics Announces That OTL-101 Has Received a Rare Paediatric Disease Designation

London, UK, July 24, 2017 / B3C newswire / -- Orchard Therapeutics Limited (“Orchard”), a clinical-stage biotechnology company dedicated to bringing transformative autologous ex-vivo gene therapies to patients with rare diseases of high unmet medical need …

Distribution channels: Technology
Published on July 17, 2017 - 13:51 GMT

RedHill Biopharma Announces Last Patient Visit in BEKINDA® Phase II Study for IBS-D

Top-line results are expected in September 2017 The randomized, double-blind, placebo-controlled Phase II study is evaluating the safety and efficacy of BEKINDA® (RHB-102) 12 mg in 127 U.S. patients with diarrhea-predominant irritable bowel syndrome (IBS- …

Distribution channels: Technology
Published on July 12, 2017 - 13:34 GMT

RedHill Biopharma Announces Expected Timeline for DSMB Meeting and Provides Update on Enrollment in the RHB-104 Phase III Study ...

The second independent Data and Safety Monitoring Board (DSMB) meeting of the RHB-104 Phase III study for Crohn’s disease (MAP US study) is planned to be held in late July 2017 and will assess the safety and efficacy of RHB-104 in the first 222 subjects …

Distribution channels: Technology

Previous 23 24 25 26 27 28 29 30 31 32 33 Next